List view / Grid view
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
25 April 2016 | By Victoria White, Drug Target Review
We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...
16 March 2016 | By Victoria White
Researchers from NIST have shown that high-throughput screening can dramatically speed up the challenging task of antimicrobial discovery...
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
2 September 2015 | By Victoria White
ESCMID advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms...
22 May 2015 | By Victoria White
Vinpocetine is an effective treatment for middle-ear infections, showing the ability to improve bacterial clearance and reduce hearing loss...
14 May 2015 | By Victoria White
Antibiotic Research UK has welcomed this latest report to come from Jim O’Neill's Review on Antimicrobial Resistance and has endorses its recommendations...
30 April 2015 | By Victoria White
Biotech companies presented new mechanisms and approaches in the global fight against infections in a pipeline session at ECCMID...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
2 December 2014 | By BioVersys and Enamine
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year...
